30 false false false false false false false false false false true false false false false false false No description of principal activity 2023-10-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 09791305 2023-10-01 2024-09-30 09791305 2024-09-30 09791305 2023-09-30 09791305 2022-10-01 2023-09-30 09791305 2023-09-30 09791305 2022-09-30 09791305 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-10-01 2024-09-30 09791305 core:FurnitureFittings 2023-10-01 2024-09-30 09791305 bus:Director1 2023-10-01 2024-09-30 09791305 bus:Director2 2023-10-01 2024-09-30 09791305 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-09-30 09791305 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-09-30 09791305 core:FurnitureFittings 2023-09-30 09791305 core:FurnitureFittings 2024-09-30 09791305 core:WithinOneYear 2024-09-30 09791305 core:WithinOneYear 2023-09-30 09791305 core:AfterOneYear 2024-09-30 09791305 core:AfterOneYear 2023-09-30 09791305 core:ShareCapital 2024-09-30 09791305 core:ShareCapital 2023-09-30 09791305 core:SharePremium 2024-09-30 09791305 core:SharePremium 2023-09-30 09791305 core:RetainedEarningsAccumulatedLosses 2024-09-30 09791305 core:RetainedEarningsAccumulatedLosses 2023-09-30 09791305 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-09-30 09791305 core:FurnitureFittings 2023-09-30 09791305 bus:Director1 2023-09-30 09791305 bus:Director1 2024-09-30 09791305 bus:Director2 2023-09-30 09791305 bus:Director2 2024-09-30 09791305 bus:Director1 2022-09-30 09791305 bus:Director1 2023-09-30 09791305 bus:Director2 2023-09-30 09791305 bus:Director1 2022-10-01 2023-09-30 09791305 bus:Director2 2022-10-01 2023-09-30 09791305 bus:SmallEntities 2023-10-01 2024-09-30 09791305 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 09791305 bus:SmallCompaniesRegimeForAccounts 2023-10-01 2024-09-30 09791305 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 09791305 bus:FullAccounts 2023-10-01 2024-09-30 09791305 core:ComputerSoftware 2023-10-01 2024-09-30 09791305 core:ComputerEquipment 2023-10-01 2024-09-30 09791305 core:ComputerSoftware 2023-09-30 09791305 core:ComputerSoftware 2024-09-30 09791305 core:ComputerEquipment 2023-09-30 09791305 core:ComputerEquipment 2024-09-30
COMPANY REGISTRATION NUMBER: 09791305
DEFINITION HEALTH LIMITED
FILLETED UNAUDITED FINANCIAL STATEMENTS
30 September 2024
DEFINITION HEALTH LIMITED
STATEMENT OF FINANCIAL POSITION
30 September 2024
2024
2023
Note
£
£
£
Fixed assets
Intangible assets
5
3,377,567
3,036,193
Tangible assets
6
21,944
24,907
-------------
-------------
3,399,511
3,061,100
Current assets
Debtors
7
506,906
195,946
Cash at bank and in hand
84,436
3,135
----------
----------
591,342
199,081
Creditors: amounts falling due within one year
8
1,809,208
2,478,386
-------------
-------------
Net current liabilities
1,217,866
2,279,305
-------------
-------------
Total assets less current liabilities
2,181,645
781,795
Creditors: amounts falling due after more than one year
9
6,607
16,607
Provisions
4,169
4,732
-------------
----------
Net assets
2,170,869
760,456
-------------
----------
Capital and reserves
Called up share capital
4,991
1,118
Share premium account
5,754,126
2,644,443
Profit and loss account
( 3,588,248)
( 1,885,105)
-------------
-------------
Shareholders funds
2,170,869
760,456
-------------
-------------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
DEFINITION HEALTH LIMITED
STATEMENT OF FINANCIAL POSITION (continued)
30 September 2024
For the year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 10 March 2025 , and are signed on behalf of the board by:
Mr S Chauhan
Director
Company registration number: 09791305
DEFINITION HEALTH LIMITED
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 SEPTEMBER 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 168 Church Road, Hove, East Sussex, BN3 2DL, UK.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
No material uncertainties that may cast significant doubt about the ability of the company to continue as a going concern have been identified by the directors. The directors consider that the uncertainty caused in the company's industry as a result of Coronavirus and the restrictions that were put in place by the government should not materially affect the company's ability to continue as a going concern. This assumption has been continued as the economy is hit by the cost of living crisis, and world economic impact of the war in Ukraine.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Foreign currencies
Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.
Intangible assets
Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at revalued amounts, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses. Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
Website/branding
-
10% straight line
Software development
-
14% straight line
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Research and development
Research expenditure is written off in the period in which it is incurred. Development expenditure incurred is capitalised as an intangible asset only when all of the following criteria are met: - It is technically feasible to complete the intangible asset so that it will be available for use or sale; - There is the intention to complete the intangible asset and use or sell it; - There is the ability to use or sell the intangible asset; - The use or sale of the intangible asset will generate probable future economic benefits; - There are adequate technical, financial and other resources available to complete the development and to use or sell the intangible asset; and - The expenditure attributable to the intangible asset during its development can be measured reliably. Expenditure that does not meet the above criteria is expensed as incurred.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Fixtures and fittings
-
20% straight line
Equipment
-
33% straight line
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Provisions
Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised as a finance cost in profit or loss in the period it arises.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 30 (2023: 30 ).
5. Intangible assets
Website/branding
Software development
Total
£
£
£
Cost
At 1 October 2023
27,813
4,784,510
4,812,323
Additions
700
1,119,867
1,120,567
---------
-------------
-------------
At 30 September 2024
28,513
5,904,377
5,932,890
---------
-------------
-------------
Amortisation
At 1 October 2023
12,353
1,763,777
1,776,130
Charge for the year
2,816
776,377
779,193
---------
-------------
-------------
At 30 September 2024
15,169
2,540,154
2,555,323
---------
-------------
-------------
Carrying amount
At 30 September 2024
13,344
3,364,223
3,377,567
---------
-------------
-------------
At 30 September 2023
15,460
3,020,733
3,036,193
---------
-------------
-------------
6. Tangible assets
Fixtures and fittings
Equipment
Total
£
£
£
Cost
At 1 October 2023
2,056
59,765
61,821
Additions
12,428
12,428
-------
---------
---------
At 30 September 2024
2,056
72,193
74,249
-------
---------
---------
Depreciation
At 1 October 2023
1,620
35,294
36,914
Charge for the year
396
14,995
15,391
-------
---------
---------
At 30 September 2024
2,016
50,289
52,305
-------
---------
---------
Carrying amount
At 30 September 2024
40
21,904
21,944
-------
---------
---------
At 30 September 2023
436
24,471
24,907
-------
---------
---------
7. Debtors
2024
2023
£
£
Trade debtors
32,100
152,696
Other debtors
474,806
43,250
----------
----------
506,906
195,946
----------
----------
8. Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans and overdrafts
182,432
198,584
Trade creditors
194,462
184,634
Social security and other taxes
597,020
519,645
Other creditors
835,294
1,575,523
-------------
-------------
1,809,208
2,478,386
-------------
-------------
9. Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
6,607
16,607
-------
---------
10. Directors' advances, credits and guarantees
During the year the directors entered into the following advances and credits with the company:
2024
Balance brought forward
Advances/ (credits) to the directors
Balance outstanding
£
£
£
Mr S Chauhan
( 151,597)
10,983
( 140,614)
Dr R Scott
24,612
( 3,850)
20,762
----------
---------
----------
( 126,985)
7,133
( 119,852)
----------
---------
----------
2023
Balance brought forward
Advances/ (credits) to the directors
Balance outstanding
£
£
£
Mr S Chauhan
( 169,741)
18,144
( 151,597)
Dr R Scott
24,612
24,612
----------
---------
----------
( 169,741)
42,756
( 126,985)
----------
---------
----------